CD86 and neoplasm: However, we report that only the UV-inactivated oncolysates derived from rVSV-NDV-infected A549 or H1437 cells were efficient in activating human DCs (CD86 high, MHC-I high, and MHC-II high) in vitro, which agrees with our previous findings of an immunogenic oncolysis that triggered DC activation in vitro and in a murine in vivo tumor model.4